Merck spends $10 billion for Verona, gaining access to its COPD medication

Ohtuvayre was launched as the first commercial product for London-based Verona Pharma, and is also being studied as a possible treatment for another chronic respiratory problem that gets worse over time: non-cystic fibrosis bronchiectasis.